Target Details
| UniProt AC | P42345 |
|---|---|
| Gene Symbol | MTOR |
| Protein Name | Serine/threonine-protein kinase mTOR |
| Organism | Homo sapiens |
| Entry Name | |
| Organism Category | Human |
| Pfam Domains | PF02259 (FAT) PF02260 (FATC) PF08771 (FRB_dom) PF23593 (HEAT_ATR) PF11865 (mTOR_dom) PF00454 (PI3_PI4_kinase) |
Summary
- Multi-target molecules 2,517
- Clinical molecules 193
- Avg pChEMBL 7.75
KEGG Pathways (53)
- AMPK signaling pathway
- Acute myeloid leukemia
- Adipocytokine signaling pathway
- Alzheimer disease
- Amyotrophic lateral sclerosis
- Apelin signaling pathway
- Autophagy - animal
- Autophagy - other
- Breast cancer
- Cellular senescence
- Central carbon metabolism in cancer
- Chemical carcinogenesis - receptor activation
- Choline metabolism in cancer
- Colorectal cancer
- Diabetic cardiomyopathy
- EGFR tyrosine kinase inhibitor resistance
- Endocrine resistance
- ErbB signaling pathway
- Gastric cancer
- Glioma
- Growth hormone synthesis, secretion and action
- HIF-1 signaling pathway
- Hepatocellular carcinoma
- Herpes simplex virus 1 infection
- Human cytomegalovirus infection
- Human immunodeficiency virus 1 infection
- Human papillomavirus infection
- Huntington disease
- Insulin resistance
- Insulin signaling pathway
- Integrin signaling
- JAK-STAT signaling pathway
- Kaposi sarcoma-associated herpesvirus infection
- Longevity regulating pathway
- Longevity regulating pathway - multiple species
- Lysosome biogenesis
- MicroRNAs in cancer
- Neutrophil extracellular trap formation
- PD-L1 expression and PD-1 checkpoint pathway in cancer
- PI3K-Akt signaling pathway
- Pancreatic cancer
- Pathways in cancer
- Pathways of neurodegeneration - multiple diseases
- Phospholipase D signaling pathway
- Prostate cancer
- Proteoglycans in cancer
- Shigellosis
- Spinocerebellar ataxia
- Th17 cell differentiation
- Thermogenesis
- Thyroid hormone signaling pathway
- Type II diabetes mellitus
- mTOR signaling pathway
Associated Diseases (2)
Active Molecules (2,517)
| InChIKey | pChEMBL | Type | Targets | Clinical | |
|---|---|---|---|---|---|
KZBVFYIUGYSPEI
|
9.3 | IC50 | 2 | — | |
PZLDVTRVPWMLFG
|
9.3 | IC50 | 5 | — | |
AIGSGJXYLHDMBA
|
9.3 | IC50 | 6 | — | |
HGOMTYLJLJSWLU
|
9.3 | IC50 | 2 | — | |
HRGYHCLHXQJDHS
|
9.3 | IC50 | 4 | — | |
OLLQSKSTOJYQJW
|
9.3 | IC50 | 2 | — | |
QUBPQLLMMSZSGD
|
9.3 | IC50 | 2 | — | |
STVCPBFHBWLKFO
|
9.3 | IC50 | 2 | — | |
JRUYCIYRCTVFIO
|
9.3 | IC50 | 2 | — | |
OBEPVKXFRQZDCB
|
9.3 | IC50 | 3 | — | |
NQNFBVOZVJAWSQ
|
9.3 | IC50 | 3 | — | |
WOZYVVSCKUPLTE
|
9.3 | IC50 | 2 | — | |
LWJMVOBSLCHODM
|
9.3 | IC50 | 2 | — | |
VPTVCYOEECUFBP
|
9.3 | IC50 | 4 | — | |
JDTLYBGUQBBSSW
|
9.3 | IC50 | 3 | — | |
KZQWIVWSZFQHSK
|
9.3 | IC50 | 2 | — | |
LRPUTZBETOGWIQ
|
9.3 | IC50 | 3 | — | |
PIBYKCQZEFWRSQ
|
9.3 | IC50 | 2 | — | |
QDYDLDKGDBEEOL
|
9.3 | IC50 | 3 | — | |
SIZCWNYHKIDIFT
|
9.3 | IC50 | 2 | — | |
CTICQSLZAWDGGR
|
9.3 | IC50 | 2 | — | |
LXKCPGRADZOFQP
|
9.3 | IC50 | 3 | — | |
YWWJGAYIUGBLMJ
|
9.3 | IC50 | 3 | — | |
CJDSQNSAHPDXGA
|
9.3 | IC50 | 3 | — | |
IUTYTXDIGUNPAA
|
9.3 | IC50 | 3 | — | |
TWXPKRFOVKTWJA
|
9.3 | IC50 | 2 | — | |
WDCVJKKGNJCIFD
|
9.3 | IC50 | 2 | — | |
KKVNBLMTQLDRSE
|
9.3 | IC50 | 2 | — | |
KXMYPFPNGHXRLC
|
9.3 | IC50 | 2 | — | |
DTIVUYHHUOLVNC
|
9.2 | IC50 | 2 | — | |
JBTCILSTBDBZLG
|
9.2 | IC50 | 3 | — | |
PMYRNYKUOVLEMF
|
9.2 | IC50 | 2 | — | |
WPNCPKGXCPBKKQ
|
9.2 | IC50 | 2 | — | |
ZXGQCEYIWIQYRV
|
9.2 | IC50 | 3 | — | |
DOIHBCAHVZCZBV
|
9.2 | IC50 | 2 | — | |
FVKLSWBTKPIXFR
|
9.2 | IC50 | 2 | — | |
KCNCCZCAVYLQAH
|
9.2 | IC50 | 3 | — | |
KPXVSFMQOAWOEC
|
9.2 | IC50 | 2 | — | |
OIYXEHIRFQIXQT
|
9.2 | IC50 | 2 | — | |
OVMBAIROGFJDTQ
|
9.2 | IC50 | 3 | — | |
SEDDHGLWJQCXTK
|
9.2 | IC50 | 2 | — | |
XGKILEKRCLGRHL
|
9.2 | IC50 | 5 | — | |
YTIWEKXIPWJYGB
|
9.2 | IC50 | 2 | — | |
AEPOITNLAPHSGR
|
9.2 | IC50 | 2 | — | |
BZXCVHXYXYFXQP
|
9.2 | IC50 | 2 | — | |
DDTZRQUKUGXHGI
|
9.2 | IC50 | 3 | — | |
DPLMXAYKJZOTKO
|
9.2 | IC50 | 5 | — | |
GMASZVAHNYVURN
|
9.2 | IC50 | 2 | — | |
MDAFZGAXBHQRNG
|
9.2 | IC50 | 2 | — | |
OLGUTDPLQANPCD
|
9.2 | IC50 | 2 | — |